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Abstract
Background—High expression of ERBB2 has been reported in medulloblastoma and 
ependymoma; EGFR is amplified and over-expressed in brainstem glioma suggesting these 
proteins as potential therapeutic targets. We conducted a molecular biology (MB) and phase II 
study to estimate inhibition of tumor ERBB signaling and sustained responses by lapatinib in 
children with recurrent CNS malignancies.
Patients and Methods—In the MB study, patients with recurrent medulloblastoma, 
ependymoma, and high-grade glioma (HGG) undergoing resection were stratified and randomized 
to pre-resection treatment with lapatinib 900 mg/m2/dose bid for 7–14 days or no treatment. 
Western blot analysis of ERBB expression and pathway activity in fresh tumor obtained at surgery 
estimated ERBB receptor signaling inhibition in vivo. Drug concentration was simultaneously 
assessed in tumor and plasma. In the phase II study, patients, stratified by histology, received 
lapatinib continuously, to assess sustained response.
Results—Eight patients, on the MB trial (4 medulloblastomas, 4 ependymomas), received a 
median of 2 courses (range: 1–6+). No intratumoral target inhibition by lapatinib was noted in any 
patient. Tumor-to-plasma ratios of lapatinib were 10–20%. In the 34 patients (14 MB, 10 HGG, 10 
ependymoma) in the phase II study, lapatinib was well-tolerated at 900 mg/m2/dose bid. The 
median number of courses in the phase II trial was 2 (range 1–12). Seven patients (3 
medulloblastoma, 4 ependymoma) remained on therapy for at least 4 courses range (4–26).
Conclusion—Lapatinib was well-tolerated in children with recurrent or CNS malignancies, but 
did not inhibit target in tumor and had little single agent activity.
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INTRODUCTION
A comprehensive study of molecular targeted therapeutics should include an assessment of 
target inhibition in vivo [1,2]. While this is relatively straightforward in preclinical model 
systems, measuring drug-target inhibition in children with recurrent deep-seated pediatric 
brain tumors is more difficult; particularly in early clinical trials when re-resection is 
generally not performed. Although we routinely measure in vivo drug activity in more 
accessible, surrogate tissues (e.g. peripheral blood mononuclear cells [3,4]), these tissues 
may not express the appropriate target protein, and their pattern of drug-target inhibition 
might not correlate with that in tumor. Thus, direct simultaneous measurement of drug 
concentration and target inhibition in tumors provides unprecedented data to correlate with 
measures of drug pharmacokinetics and clinical response [5,1,2].
Recently, we reported the results of a phase I study of the Epidermal Growth Factor 
Receptor (EGFR) and ERBB2 tyrosine kinase inhibitor, lapatinib, in children with recurrent 
brain tumors [6]. High expression of ERBB2 has been reported in medulloblastoma [7,8] 
and ependymoma [9]; EGFR is amplified and over-expressed in brainstem glioma [10] 
suggesting these proteins as potential therapeutic targets. The combination of lapatinib and 
capecitabine has proven active in first line treatment of brain metastases from ERBB-2 
positive breast cancer [11]. Lapatinib is FDA approved for treatment of postmenopausal 
women with hormone receptor positive metastatatic breast cancer that overexpresses 
ERBB2.
To better understand efficacy and EGFR/ERB2 signaling blockade of lapatinib in brain 
tumors, we conducted a molecular biology and phase II study in children. Children with 
local recurrence of medulloblastoma/primitive neuroectodermal tumor (PNET), 
ependymoma or high-grade glioma (HGG) for whom surgical resection was planned were 
randomized to receive lapatinib or no drug for 7–10 days prior to surgery. Tumors were 
removed and levels of intratumoral EGFR/ERBB2 receptor activity and drug concentration 
were measured. Patients with post-operative residual recurrent medulloblastoma/PNET, 
HGG or ependymoma were also included in Phase II estimates of sustained response rates to 
lapatinib.
PATIENTS AND METHODS
Patient Eligibility
Common eligibility criteria for both the molecular biology and phase II study included 
patients aged ≤ 21 years with a histological verified medulloblastoma/PNET, ependymoma 
and HGG (anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, anaplastic 
oligodendroglioma) refractory to conventional therapy. Other eligibility criteria were similar 
to those employed in our phase I trial [3]. For the molecular biology study, patients needed 
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to have tumors for which surgical resection was clinically indicated and were amenable to 
receiving lapatinib for 7–14 days prior to resection. For the phase II study, patients had to 
have measureable disease. Informed consent was obtained from patients, parents or 
guardians, and assent was obtained as appropriate at the time of protocol enrollment. The 
institutional review boards of each PBTC institution approved the protocol before patient 
enrollment and continuing approval was maintained throughout the study.
Drug Administration
Lapatinib, supplied by the Cancer Therapy Evaluation Program (NCI, Bethesda, MD) as a 
250 mg oval, film-coated tablet, was administered orally, twice daily. Each course was 28 
days in length. Tablets could be cut in half; total daily doses were rounded to the nearest 125 
mg. For patients with difficulty swallowing, lapatinib tablets were added to 2–4 oz of water 
or Kool-Aid or 3 oz of chocolate milk and stirred to form a suspension. A dosing nomogram 
based on body surface area and dosage level (rounded to the nearest 125 mg) was used to 
minimize interpatient dosing variability. The lapatinib dosage was 900 mg/m2/dose twice 
daily, the MTD established in the recently published phase I study. Patients could receive up 
to 26 courses in the absence of disease progression.
Dose Modifications
Hematologic dose modifying toxicity was defined as grade 4 neutropenia or grade 3 or 4 
thrombocytopenia related to lapatinib. Non-hematologic dose modifying toxicity was 
defined as any grade 3 or 4 non-hematological toxicity with the specific exclusion of: grade 
3 nausea and vomiting controlled with adequate antiemetics; grade 3 fever or infection; 
grade 3 diarrhea responsive to optimal use of loperamide; grade 3 or 4 hypokalemia, 
hypophosphatemia or hypomagnesemia which resolve to ≤ grade 2 by supplementation 
within 7 days. Any grade 2 non-hematological toxicity that persisted for > 7 days and was 
considered sufficiently intolerable by patients as to warrant treatment interruption and/or 
dose reduction was considered dose-limiting.
Pretreatment Evaluations and Evaluations During Therapy
Pretreatment evaluations included a history, physical examination, performance status, 
disease evaluation, complete blood count (CBC), electrolytes, renal and liver function tests, 
pregnancy test for female patients of childbearing age, echocardiogram/gated radionuclide 
study (MUGA). CBCs were obtained every 2 weeks during course 1 and prior to each 
subsequent course. History, physical examinations, and serum chemistries were obtained 
every 2 weeks in course 1 and prior to each subsequent course. Echocardiogram/MUGA was 
obtained at the end of course 2 and every 12 weeks thereafter.
Response Criteria
Disease evaluations were obtained at baseline, after course 2 and every other course, 
thereafter. Tumor response was defined as follows: complete response (CR), disappearance 
of all measurable lesions on magnetic resonance imaging (MRI); partial response (PR), 
≥50% reduction in tumor size by bidimensional measurement on a stable or decreasing dose 
of corticosteroids, accompanied by a stable or improving neurological exam and maintained 
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for at least 8 weeks; progressive disease (PD), worsening neurologic status or >25% increase 
in the bidimensional measurement, or appearance of new lesions, or increasing 
corticosteroids doses; stable disease (SD), MRI response does not meet the criteria for other 
categories, with stable neurologic examination and corticosteroid dose.
Pharmacokinetic Studies
Pharmacokinetic studies were performed in all consenting patients on the molecular biology 
and Phase II studies. In the molecular biology study, patients had a plasma sample and a 
sample of tumor tissue obtained during surgery. Tumor tissue harvested during surgery was 
weighed, diluted in an appropriate volume of buffer, and mechanically homogenized. 
Lapatinib concentrations were determined by a liquid chromatography electrospray tandem 
mass spectrometry (LC-ESI-MS/MS) method, with a lower limit of quantitation of 1 ng/ml 
in plasma and 10 ng/ml in brain tumor tissue extracts [12]. In the Phase II study plasma 
samples were obtained with the first dose of Courses 1 and 2. Serial whole blood samples (2 
ml) were collected in heparinized tubes before the dose, and 0.5, 1, 1.5, 3, 6, and 8 hours 
after administration.12 Pharmacokinetic parameters for lapatinib were calculated using 
noncompartmental methods. For each patient, the maximum concentration (Cmax) and time 
to maximum concentration (tmax) were the observed values. The area under the plasma 
concentration-time curve (AUC0→t where t was the last measured time point) was calculated 
by the trapezoidal rule.
ERBB Receptor Expression and Signal Activity
Expression and activation of the ERBB signaling network was analyzed in tumor samples 
using previously described immunohistochemical (IHC) techniques [7,9]. Fixed tumor 
material was also used for central histopathology review to confirm diagnosis. To determine 
lapatinib’s ability to inhibit tumor ERBB receptor signaling, we compared pathway activity 
in tumors from patients who received drug, with those who did not. Fresh frozen tumor 
material was harvested at surgery following 7–14 days of lapatinib or placebo or from 
pretrial tumor samples, and subjected to quantitative western blot analysis of phospho-
EGFR and phospho-ERBB2, normalized to the level of total receptor protein and total 
(housekeeping protein) in each sample. As another measure of baseline ERBB signaling 
activity in tumor samples, we also analyzed an additional cohort of ependymomas (n=14) 
collected as part of the Phase I and II components of this study. These data were correlated 
with parallel pharmacokinetic measures of tumor drug concentrations and patient 
progression free survival (PFS).
Statistical Considerations
The primary objective of the study was to determine the true sustained objective response 
(CR and PR) rate to lapatinib in children with recurrent or refractory medulloblastoma/
PNET (Stratum A), HGG (Stratum B) and ependymoma (Stratum C). The response 
evaluation period was set as 4 courses for Strata A and B and as 6 courses for Stratum C. 
Only responses sustained for at least 8 weeks were counted towards the primary endpoint. 
Patients who received <50% of the expected total dose or patients who withdrew from 
treatment during the first 2 courses for reasons other than progressive disease or death were 
considered inevaluable for response and were replaced. Simon’s Minimax Two Stage 
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Design was used separately for each stratum with α=10% and 90% power. For Stratum A, 
response rates of 15% (unacceptable) vs. 35% (desirable) were used which lead to a first 
stage sample size of 17 and a total sample size of 32. At the interim analysis 3 or more 
responses were needed to expand the sample size to 32 where 8 or more responses would 
lead to declaring the trial a success. Though applied separately, the design for Strata B and C 
were identical with response rates of 5% (unacceptable) vs. 25% (desirable). This led to a 
sample size of 13 at the interim analysis and an overall sample size of 20. One response was 
adequate to expand the cohort beyond the interim analysis and 3 or more responses were 
needed to declare the trial a success in these two strata. Ten patients (3 in Stratum A, 3 in 
Stratum B and 4 in Stratum C) who were treated at the MTD during the Phase I trial and 
who met the eligibility criteria for the Phase II trial were counted towards the accrual of the 
Phase II trial. All summary statistics and tables provided here include these patients.
The molecular biology trial was designed to detect 5% vs. 60% inhibition of ERBB receptor 
signaling in the patients who were randomized to not receive vs. to receive lapatinib for 7–
14 days prior to surgery, respectively. The molecular biologist who determined the level of 
receptor phosphorylation was masked to the treatment groups. While the randomization was 
stratified, there was no a priori reason to expect that the agent’s ability to inhibit ERBB 
signaling would differ across histologies. Hence the design was based on an overall 
comparison of ERBB signaling between the two randomized groups. The sample size 
calculation utilized a binomial distribution with α=5% and 90% power resulting in a sample 
size of 28 patients whose tumors expressed ERBB. Based on previously published 
information [13,14] it was estimated that up to 45 patients would have to be randomized to 
accrue 28 patients whose tumors expressed ERBB. While the two trials were designed 
separately, the accrual to the Molecular Biology trial was contingent upon accrual being 
open for the Phase II trial. Hence when accrual to a stratum of the phase II trial was 
suspended or closed, accrual to the corresponding stratum of the Molecular Biology trial 
was also suspended or closed.
RESULTS
Patient Characteristics
Eight patients, 4 with ependymoma and 4 with medulloblastoma were enrolled on the 
molecular biology study; one medulloblastoma patient was not evaluable for the molecular 
biology objective as no fresh frozen tissue was submitted. Forty-four patients, all eligible, 
were enrolled on the phase II study; 17 on stratum A (medulloblastoma), 13 on stratum B 
(HGG) and 14 on stratum C (ependymoma). Three were inevaluable for response because of 
progression prior to treatment (n=1) or withdrawal from treatment during the first course of 
therapy (n=2). Table 1 and 2 summarize the characteristics of the eligible patients in the 
molecular biology and phase II studies, respectively. The median number of courses in all 
strata was 2 (range, 1–26). The accrual to the phase II trial was 2.5 to 3 times faster than 
anticipated and accrual to the molecular biology trial was on target. However, all 3 strata 
were closed for lack of efficacy following planned interim analyses, thus limiting enrollment 
to the molecular biology study. No pre-, intra, or post-operative complications were 
observed among patients treated within the molecular biology study.
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ERBB Receptor Inhibition in the Molecular Biology Study
Of seven evaluable patients on the molecular biology study, four with ependymoma and 
three with medulloblatoma were randomized to receive lapatinib or no-treatment, 
respectively, prior to surgery. No significant difference was observed in the relative 
phosphorylation (RPS) of the EGFR receptor in tumors exposed to lapatinib (median 
RPS=0.94, range 0.16–3.07) relative to no treatment (median RPS=0.82, range 0.68–3.24) 
by western blotting. The RPS of ERBB2 in lapatinib treated tumors (median=0.21, range 
0.03–0.44) was less than half of that observed in untreated tumors (median=0.50, range 
0.05–1.66), although the numbers were insufficient for adequate assessment of statistical 
significance. A broad range of EGFR and ERBB2 RPS was observed in the 14 control 
patients and was not significantly different from either placebo or control treated patients.
Formalin fixed paraffin embedded (FFPE) tumor material was available for 25 patients (9, 
medulloblastoma; 7 glioma; 9 ependymoma) in the Phase II trial. As reported previously 
total (P=0.04) and phospho-ERBB2 levels were highest in ependymomas [6]. No significant 
relationship was observed between time to progression and IHC determined expression and 
phosphorylation of EGFR, ERBB2, ERK or pS6 in any stratum.
Pharmacokinetics
Three and 16 patients consented to pharmacokinetic studies on the molecular biology and 
phase II studies, respectively. In the three patients for whom perioperative tumor and plasma 
samples were obtained, the median (range) plasma and tumor lapatinib values were 2170 
ng/ml (973 to 5330 ng/ml) and 472 ng/g (173 to 599 ng/g), respectively. Although they 
varied widely, lapatinib brain tumor penetration reached 10 to 20% of the observed plasma 
concentration (0.18, 0.11, and 0.22).
Of the 16 phase II patients studied, 5 had repeat studies during the second course. In 13 
patients during course 1, the median (range) lapatinib maximum plasma concentration and 
time of maximum plasma concentration were 5050 ng/ml (1915 to 10500 ng/ml) and 3.2 hr 
(1.5 to 8.9 hr), respectively. In five patients studied at steady-state (after course 1), the 
median (range) lapatinib maximum plasma concentration and time of maximum plasma 
concentration were 5080 ng/ml (2530 to 10300 ng/ml) and 3.0 hr (1.5 to 8.1 hr), 
respectively. No apparent effect of dexamethasone upon lapatinib systemic exposure was 
noted in this small number of patients.
Toxicity
All patients who received at least 1 dose of lapatinib were evaluable for assessing toxicity. 
Tables 3 and 4 summarize the number of adverse events that were ≥ Grade 2, attributed to 
therapy and observed in > 10% of evaluable patients in at least 1 stratum for the molecular 
biology and phase II studies, respectively. Lapatinib was well-tolerated. The most common 
grade 3 and 4 adverse events in the molecular biology and phase II studies included diarrhea 
(7 episodes in 7 patients), hypokalemia (7 episodes in 6 patients) and lymphopenia (4 
episodes in 4 patients).
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Responses
No objective responses (OR) were reported. Prolonged SD (≥ 4 courses of therapy) was 
observed in 3 patients (4, 6 and 26 courses, respectively) in stratum A (medulloblastoma/
PNET) and 4 patients in stratum C (ependymoma) (4,12, 21 and 26 courses, respectively) in 
the phase II study.
DISCUSSION
This study demonstrates that lapatinib was well-tolerated, but had little activity in children 
with recurrent CNS malignancies. No objective responses were observed and only 7 of 44 
phase II patients had SD for ≥ 4 courses. Similar to adult studies, the most common side 
effects included diarrhea and rash.
The plasma lapatinib PK profile was similar to that measured in our phase I study [6], but, to 
our knowledge, this is the first published report of intratumoral lapatinib concentrations in 
children with recurrent CNS malignancies. The range and time of maximum plasma 
concentration values overlapped with those published from the phase I study at the MTD. 
We reported an effect of dexamethasone in our phase I study, but in this small cohort of 
patients we did not observe a similar effect [6]. The lapatinib plasma concentration values 
identified in our study were similar to those reported by Guo and colleagues in their studies 
of adult glioblastoma (~900 to 5000 ng/ml in the two studies); however, we observed much 
lower lapatinib levels in tumor (~10 to 20% of simultaneous plasma sample) [15]: 
Intratumoral concentrations reported by Guo and colleagues ranged from 3500 to 12,600 
ng/ml compared with 970 to 5330 ng/ml in our study. Results from a more recent study of 
lapatinib CNS distribution in mice harboring MDA-MD-231-BR-HER2 xenografts also 
reported low lapatinib penetration in CNS metastases (e.g., ~1.3 to 2.8% of matching plasma 
concentrations) [16]. Further studies will be required to determine if differences in blood-
tumor barriers among various cancers account for these observed differences in drug 
penetration.
Unique to our study was measurement of target inhibition in brain tumors resected from 
lapatinib treated children. No significant difference in the RPS of the EGF or ERBB2 
receptors was observed in tumors exposed to lapatinib compared to untreated tumor. These 
data are compatible with the low intratumoral concentrations of lapatinib measured in 
tumors. Intratumoral concentrations in our patients ranged from 183 to 634 nM; significantly 
less than concentrations required to inhibit ERBB2 in isolated cells, including those 
overexpressing ERBB2 [17]. Although these concentrations are above the Kd for binding of 
lapatinib to free EGFR and ERBB2 protein (3 and 13, nM respectively),16 lapatinib is highly 
protein-bound, therefore actual free lapatinib levels in the brain tumors in our studies are 
likely to be closer to 1–6 nM (1% of total) [16]. Thus, we conclude that lapatinib penetrates 
pediatric brain tumors at concentrations below that required to inhibit the ERBB receptors. 
This poor penetration may explain the observed lack of molecular and clinical activity in our 
study. Recent data in adults with NF2 and vestibular schwanommas, have shown that, 
despite biologically relevant concentrations of lapatinib in tumor tissue (15.52 micromolar), 
tumor levels of EGFR, ERB2, ERK, and AKT phosphorylation were similar between 
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patients treated with lapatinib and placebo implying that much higher levels of lapatinib may 
be required to inhibit ERBB receptors in vivo compared to cells in vitro [18].
In summary, lapatinib’s lack of intratumoral target inhibition and efficacy in children with 
recurrent CNS tumors may be explained by the fact that intratumoral lapatinib 
concentrations were well below the IC50 required to inhibit growth in vitro, and were 
slightly below those required to inhibit the EGFR and ERBB receptors.
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Table 1
Patients Characteristics of Eligible Patients (n=8) in the Molecular Biology study
Stratum A Stratum C
Number Number
Characteristic
Patients enrolled 4 4
Eligible patients 4 4
Male: female 3:1 3:1
AGE (Years)
  Median 8.8 8.5
  Range 3.1–20.1 5.8–11.2
Number Number
Diagnosis
  Ependymoma, Anaplastic 0 4
  Medulloblastoma, NOS 4 0
Prior therapy
  Radiotherapy only 1
  Chemotherapy and radiotherapy 4 3
Courses of lapatinib
  Median (range) 1.5 (1–5) 4 (1–6)
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Table 3
Number of Adverse Events (≥ Grade 2) attributed to therapy in patients in each stratum in the Molecular 
Biology Phase
Number of Episodes for Each Toxicity. (Within a patient, the highest grade is reported for each episode)
Toxicity
Stratum A Stratum C
Grade Grade
2 3 2 3
Diarrhea 1 2
Anorexia 3 2
Vomiting 1 1 1
Fatigue 1
Rash/desquamation 1
dehydration 1
Pain (abdomen NOS) 1
Fever I in the absence of neutropenia 1
ALT, SGPT (serum glutamic pyruvic transaminase) 1 1 1 1
hypokalemia 1 2
hypophosphatemia 1
hyperbilirubinemia 1
AST, SGOT (serum glutamic oxaloacetic transaminase) 1 1
Sodium, serum-low (hyponatremia) 1
Neutrophils/granulocytes (ANC/AGC) 1 .
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